The Intersection of Lynch Syndrome and Hematological Malignancies: A Rare Short Report
- PMID: 40734770
- PMCID: PMC12304074
- DOI: 10.1002/jha2.70116
The Intersection of Lynch Syndrome and Hematological Malignancies: A Rare Short Report
Abstract
Lynch syndrome (LS), which is an autosomal dominant disorder caused primarily by germline pathogenic variants of mismatch repair (MMR) genes, cases a number of malignancies. Hematologic malignancies are not included as related tumors of LS because it has not yet been established whether the carcinogenesis of hematologic malignancies is associated with MMR genes. A 75-year-old woman was admitted to our hospital with acute myeloid leukemia (AML) that had progressed from myelodysplastic syndrome (MDS). She had a history of multiple myeloma (MM) and multiple tumors associated with LS. Genetic testing revealed extensive homozygous deletions ranging from Exon 9 of EPCAM to Exons 1-6 of MSH2. Finally, we diagnosed her with LS. It revealed that the MSH2 homo-deletion occurred in myeloid cells after the onset of MM. Immunohistochemistry for MMR proteins on bone marrow specimens at MDS showed the loss of staining for the MSH2 and MSH6 proteins in myeloid cells. However, microsatellite instability was negative in spite of the large homozygous deletion of MSH2. It remains unclear whether the homo-deletion of MSH2 is involved in the development of MDS/AML. Future studies are warranted to confirm the impact of MMR variants on the pathogenesis/chemoresistance of myeloid neoplasms. Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission.
© 2025 The Author(s). eJHaem published by British Society for Haematology and John Wiley & Sons Ltd.
Conflict of interest statement
Masako Torishima: Employment: KONICA MINOLTA JAPAN, INC. Seishi Ogawa: Funding: Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science (JSPS), Chordia Therapeutics Inc., Eisai Co. Ltd., and Otsuka Pharmaceutical Co. Ltd. Shinji Kosugi: Employment: KONICA MINOLTA JAPAN, INC. The other authors declare no conflicts of interest.
Figures


References
-
- Lynch H. T., Snyder C. L., Shaw T. G., Heinen C. D., and Hitchins M. P., “Milestones of Lynch Syndrome: 1895–2015,” Nature Reviews Cancer 15 (2015): 181–194. - PubMed
-
- Sheikhha M. H., Tobal K., and Liu Yin J. A., “High Level of Microsatellite Instability but Not Hypermethylation of Mismatch Repair Genes in Therapy‐Related and Secondary Acute Myeloid Leukemia and Myelodysplastic Syndrome,” British Journal of Haematology 117 (2002): 359–365. - PubMed
-
- Mao G., Yuan F., Absher K., et al., “Preferential Loss of Mismatch Repair Function in Refractory and Relapsed Acute Myeloid Leukemia: Potential Contribution to AML Progression,” Cell Research 18 (2008): 281–289. - PubMed
-
- Vasen H. F., Watson P., Mecklin J. P., and Lynch H. T., “New Clinical Criteria for Hereditary Nonpolyposis Colorectal Cancer (HNPCC, Lynch Syndrome) Proposed by the International Collaborative Group on HNPCC,” Gastroenterology 116 (1999): 1453–1456. - PubMed
-
- Aronson M., Colas C., Shuen A., et al., “Diagnostic Criteria for Constitutional Mismatch Repair Deficiency (CMMRD): Recommendations From the International Consensus Working Group,” Journal of Medical Genetics 59 (2022): 318–327. - PubMed
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous